ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MYL Mylan NV

15.855
0.00 (0.00%)
04 Apr 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Mylan NV NASDAQ:MYL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 15.855 15.71 15.90 0 01:00:00

Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules

15/10/2009 12:30pm

PR Newswire (US)


Mylan NV (NASDAQ:MYL)
Historical Stock Chart


From Apr 2020 to Apr 2025

Click Here for more Mylan NV Charts.
PITTSBURGH, Oct. 15 /PRNewswire-FirstCall/ -- Mylan Inc. (NASDAQ:MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Topiramate Capsules (Sprinkle), 15 mg and 25 mg. Topiramate Capsules (Sprinkle) are the generic version of Ortho McNeil's anticonvulsant Topamax® Sprinkle Capsules, 15 mg and 25 mg. For the 12 months ending June 30, 2009, Topiramate Capsules (Sprinkle) had U.S. sales of approximately $58 million for the same strengths, according to IMS Health. Mylan has launched this product. Currently, Mylan has 121 ANDAs pending FDA approval representing $85.7 billion in annual brand sales, according to IMS Health. Thirty-four of these pending ANDAs are potential first-to-file opportunities, representing $17.9 billion in annual brand sales, according to IMS Health. Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit http://www.mylan.com/. DATASOURCE: Mylan Inc. CONTACT: Michael Laffin (Media), +1-724-514-1968; Dan Crookshank (Investors), +1-724-514-1813 Web Site: http://www.mylan.com/

Copyright

1 Year Mylan NV Chart

1 Year Mylan NV Chart

1 Month Mylan NV Chart

1 Month Mylan NV Chart

Your Recent History

Delayed Upgrade Clock